In research on hepatic carcinoma, TREM-1 expressing TAMs exhibited as the fundamental bridge to enhance CCR6+ Foxp3+ Treg accumulation, which disabled targeting PD-1 therapy, while the blockade on TREM-1+ TAMs revived the therapeutic activity (Wu et al., 2019). This evidence concerns the gene TREM1 and hepatocellular carcinoma.